The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases

Paul W. Sperduto, Wen Jiang, Paul D. Brown, Steve Braunstein, Penny Sneed, Daniel A. Wattson, Helen A. Shih, Ananta Bangdiwala, Ryan Shanley, Natalie A. Lockney, Kathryn Beal, Emil Lou, Thomas Amatruda, William A. Sperduto, John P. Kirkpatrick, Norman Yeh, Laurie E. Gaspar, Jason K. Molitoris, Laura Masucci, David RobergeJames Yu, Veronica Chiang, Minesh Mehta

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Purpose Brain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients. Methods and Materials We created a retrospective multi-institutional database of 823 patients with melanoma and brain metastases diagnosed between 2006 and 2015. Clinical parameters, gene mutation status (BRAF, C-KIT, NRAS), and treatment were correlated with survival. Treatment patterns and outcomes were compared with a prior era (1985-2005). Results BRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months. MS for BRAF-positive and BRAF-negative patients was 13 months and 9 months, respectively (P=.02). There was no significant difference in MS in patients with or without NRAS or C-KIT mutations. The time from primary diagnosis to brain metastasis did not vary by mutation and was not associated with survival after the diagnosis of brain metastases. MS for the 1985 to 2005 and 2006 to 2015 cohorts was 6.7 months and 10.0 months, respectively (P<.01). Reflecting treatment-trend changes, use of whole-brain radiation therapy decreased from 48% to 26% during this period. Among BRAF-positive patients, 71% received targeted BRAF and/or MEK inhibitors and 57% received some combination of targeted therapy, chemotherapy, and/or immunotherapy. Conclusions For melanoma patients with brain metastases, BRAF-positive patients survive longer than BRAF-negative patients and overall survival has improved from 1985-2005 to 2006-2015.

Original languageEnglish (US)
Pages (from-to)1069-1077
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume98
Issue number5
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases'. Together they form a unique fingerprint.

  • Cite this

    Sperduto, P. W., Jiang, W., Brown, P. D., Braunstein, S., Sneed, P., Wattson, D. A., Shih, H. A., Bangdiwala, A., Shanley, R., Lockney, N. A., Beal, K., Lou, E., Amatruda, T., Sperduto, W. A., Kirkpatrick, J. P., Yeh, N., Gaspar, L. E., Molitoris, J. K., Masucci, L., ... Mehta, M. (2017). The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 98(5), 1069-1077. https://doi.org/10.1016/j.ijrobp.2017.03.030